Preliminary Phase 2 data of TZP-102 for diabetic gastroparesis to be presented at ACG annual meeting

Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine and Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present preliminary TZP-102 Phase 2 data at this year's ACG annual meeting. The event is being held at the Henry B. Gonzalez Convention Center in San Antonio TX, October 15-20, 2010. Professor Wo is scheduled to speak on Wednesday, October 20th at 8:50am in Ballroom C1.

“An orally administered ghrelin agonist (TZP-102) decreases the overall severity of symptoms of diabetic gastroparesis (GP): Phase 2 Proof of Concept Study - Preliminary results”

The presentation entitled, "An orally administered ghrelin agonist (TZP-102) decreases the overall severity of symptoms of diabetic gastroparesis (GP): Phase 2 Proof of Concept Study - Preliminary results" will summarize the beneficial effects of TZP-102 on the multi-component gastroparesis symptom complex.

Source:

 Tranzyme Pharma

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Accelerate Your Research: Dispen3D Harnesses the Power of 3D Models